We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Should You Buy GTBIF Stock After Marijuana Reclassification Order?
Read MoreHide Full Article
Key Takeaways
GTBIF has rallied nearly 35% in a month after an executive order to move marijuana to Schedule III.
Rescheduling could ease IRS 280E, thereby improving profitability and net income visibility for GTBIF.
Green Thumb faces pricing pressure as Q3 comps fell 7% and gross margin dropped 200 basis points to 49.4%.
Shares of Green Thumb Industries (GTBIF - Free Report) soared nearly 35% in the past month, all thanks to an executive order signed by President Trump directing federal agencies to reschedule marijuana at the federal level.
Although this order was officially announced last Thursday, investor positioning had been building well before the announcement. Several third-party reports over the past several weeks had increasingly pointed to imminent action from the White House, prompting shares of several U.S.-listed cannabis operators, including Green Thumb, to rally ahead of the formal order.
Marijuana Reclassification Marks a Positive Regulatory Shift for GTBIF
The executive order directs federal agencies to expedite the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This move formally acknowledges the medical value of cannabis at the federal level and represents one of the most meaningful regulatory developments for the U.S. cannabis industry in years.
For operators like Green Thumb, rescheduling holds the potential to materially improve long-term profitability. Most notably, it could eliminate the application of IRS Code 280E, which currently prevents cannabis companies from deducting ordinary business expenses and significantly inflates effective tax rates. Any relief on this front would improve net income visibility and cash flow generation over time.
Reclassification may also support broader medical research efforts and enhance the legitimacy of cannabis-based therapies, potentially expanding adoption within regulated healthcare channels. These developments could benefit scaled, profitable operators with established consumer packaged goods (CPG) and medical portfolios, including Green Thumb.
That said, the executive order does not outline a specific implementation timeline or address federal legalization of adult-use cannabis. While these limitations introduce some uncertainty, the directive signals a clear shift in federal policy and marks an important step toward longer-term regulatory normalization for the industry.
However, an investment decision cannot be based on this development alone. A closer look at GTBIF’s broader fundamentals should provide a better context on how to play the stock following this regulatory shift.
What sets Green Thumb apart from many peers is its vertically integrated model — cultivating, processing and selling cannabis through its own retail and wholesale operations. However, with 100% of the company’s revenues tied to U.S. markets, it remains highly exposed to domestic regulatory risks, particularly the lack of federal legalization, which continues to restrict access to capital and interstate commerce.
Green Thumb’s third-quarter 2025 revenues rose nearly 2% year over year to more than $291 million. The quarter benefited from continued strength in the company’s CPG portfolio and incremental contributions from newer adult-use markets, including Minnesota. However, pricing pressure across existing retail markets partially offset these gains. Comparable store sales (open at least 12 months) declined 7% during the quarter, reflecting heightened competition and softer consumer demand.
Profitability metrics were mixed. Gross margin declined 200 basis points year over year to 49.4%, primarily due to continued price compression across key markets. However, EPS (excluding one-time gains) remained flat year over year at 4 cents, underscoring Green Thumb’s operational resilience amid a challenging pricing environment.
Looking ahead, we expect Green Thumb to remain under pressure due to persistent pricing compression in maturing markets. While the company continues to prioritize cash flow and prudent cost management, margin expansion could remain elusive without a rebound in retail pricing dynamics. Management expects fourth-quarter 2025 revenues to be sequentially flat to up low single digits.
Cutthroat Competition
Green Thumb operates in an increasingly competitive U.S. cannabis market, where price compression and oversupply are weighing on most operators. The company faces stiff competition from peers like Canopy Growth (CGC - Free Report) and Cresco Labs (CRLBF - Free Report) , both of which are also pursuing similar expansion and cost-control initiatives.
What further differentiates the competitive landscape is geographic exposure. Canopy Growth and Cresco Labs have been expanding their presence outside the United States, targeting the growing cannabis markets in Europe and other regions. This diversification provides them with additional growth avenues and some insulation from U.S.-specific risks. In contrast, Green Thumb remains fully reliant on the fragmented and crowded domestic market.
GTBIF Stock Performance and Estimates
Shares of Green Thumb have underperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
Movements in EPS estimates for 2025 and 2026 have been mixed over the past 60 days.
Image Source: Zacks Investment Research
How to Play GTBIF Stock?
While marijuana reclassification represents a meaningful policy milestone, it does not fundamentally alter the near-term operating outlook for cannabis companies focused on adult-use markets. The current regulatory focus remains on the medical component of cannabis, leaving uncertainty around broader legalization, interstate commerce and banking reform. As a result, we expect the financial uplift from reclassification to be gradual rather than immediate.
Although a stable revenue stream and the ability to generate free cash flow offer some support for GTBIF stock, the company’s significant exposure to the U.S. market, along with pricing pressures, continues to strain its financial profile. While existing shareholders may choose to maintain exposure in anticipation of longer-term reform, prospective investors are advised to wait for clearer evidence that regulatory progress is translating into sustainable earnings growth. Until then, a cautious approach toward this Zacks Rank #3 (Hold) stock remains warranted.
Image: Bigstock
Should You Buy GTBIF Stock After Marijuana Reclassification Order?
Key Takeaways
Shares of Green Thumb Industries (GTBIF - Free Report) soared nearly 35% in the past month, all thanks to an executive order signed by President Trump directing federal agencies to reschedule marijuana at the federal level.
Although this order was officially announced last Thursday, investor positioning had been building well before the announcement. Several third-party reports over the past several weeks had increasingly pointed to imminent action from the White House, prompting shares of several U.S.-listed cannabis operators, including Green Thumb, to rally ahead of the formal order.
Marijuana Reclassification Marks a Positive Regulatory Shift for GTBIF
The executive order directs federal agencies to expedite the reclassification of marijuana from Schedule I to Schedule III under the Controlled Substances Act. This move formally acknowledges the medical value of cannabis at the federal level and represents one of the most meaningful regulatory developments for the U.S. cannabis industry in years.
For operators like Green Thumb, rescheduling holds the potential to materially improve long-term profitability. Most notably, it could eliminate the application of IRS Code 280E, which currently prevents cannabis companies from deducting ordinary business expenses and significantly inflates effective tax rates. Any relief on this front would improve net income visibility and cash flow generation over time.
Reclassification may also support broader medical research efforts and enhance the legitimacy of cannabis-based therapies, potentially expanding adoption within regulated healthcare channels. These developments could benefit scaled, profitable operators with established consumer packaged goods (CPG) and medical portfolios, including Green Thumb.
That said, the executive order does not outline a specific implementation timeline or address federal legalization of adult-use cannabis. While these limitations introduce some uncertainty, the directive signals a clear shift in federal policy and marks an important step toward longer-term regulatory normalization for the industry.
However, an investment decision cannot be based on this development alone. A closer look at GTBIF’s broader fundamentals should provide a better context on how to play the stock following this regulatory shift.
Pricing Pressures Hinder GTBIF’s Financial Performance
What sets Green Thumb apart from many peers is its vertically integrated model — cultivating, processing and selling cannabis through its own retail and wholesale operations. However, with 100% of the company’s revenues tied to U.S. markets, it remains highly exposed to domestic regulatory risks, particularly the lack of federal legalization, which continues to restrict access to capital and interstate commerce.
Green Thumb’s third-quarter 2025 revenues rose nearly 2% year over year to more than $291 million. The quarter benefited from continued strength in the company’s CPG portfolio and incremental contributions from newer adult-use markets, including Minnesota. However, pricing pressure across existing retail markets partially offset these gains. Comparable store sales (open at least 12 months) declined 7% during the quarter, reflecting heightened competition and softer consumer demand.
Profitability metrics were mixed. Gross margin declined 200 basis points year over year to 49.4%, primarily due to continued price compression across key markets. However, EPS (excluding one-time gains) remained flat year over year at 4 cents, underscoring Green Thumb’s operational resilience amid a challenging pricing environment.
Looking ahead, we expect Green Thumb to remain under pressure due to persistent pricing compression in maturing markets. While the company continues to prioritize cash flow and prudent cost management, margin expansion could remain elusive without a rebound in retail pricing dynamics. Management expects fourth-quarter 2025 revenues to be sequentially flat to up low single digits.
Cutthroat Competition
Green Thumb operates in an increasingly competitive U.S. cannabis market, where price compression and oversupply are weighing on most operators. The company faces stiff competition from peers like Canopy Growth (CGC - Free Report) and Cresco Labs (CRLBF - Free Report) , both of which are also pursuing similar expansion and cost-control initiatives.
What further differentiates the competitive landscape is geographic exposure. Canopy Growth and Cresco Labs have been expanding their presence outside the United States, targeting the growing cannabis markets in Europe and other regions. This diversification provides them with additional growth avenues and some insulation from U.S.-specific risks. In contrast, Green Thumb remains fully reliant on the fragmented and crowded domestic market.
GTBIF Stock Performance and Estimates
Shares of Green Thumb have underperformed the industry year to date, as shown in the chart below.
Image Source: Zacks Investment Research
Movements in EPS estimates for 2025 and 2026 have been mixed over the past 60 days.
Image Source: Zacks Investment Research
How to Play GTBIF Stock?
While marijuana reclassification represents a meaningful policy milestone, it does not fundamentally alter the near-term operating outlook for cannabis companies focused on adult-use markets. The current regulatory focus remains on the medical component of cannabis, leaving uncertainty around broader legalization, interstate commerce and banking reform. As a result, we expect the financial uplift from reclassification to be gradual rather than immediate.
Although a stable revenue stream and the ability to generate free cash flow offer some support for GTBIF stock, the company’s significant exposure to the U.S. market, along with pricing pressures, continues to strain its financial profile. While existing shareholders may choose to maintain exposure in anticipation of longer-term reform, prospective investors are advised to wait for clearer evidence that regulatory progress is translating into sustainable earnings growth. Until then, a cautious approach toward this Zacks Rank #3 (Hold) stock remains warranted.
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.